Parenteral Focus ZebraSci specializes in parenteral combination product development and testing, offering end-to-end support from early feasibility through validation and post-commercialization investigations. This positions them as a turnkey partner for biotech and pharma companies pursuing combination therapies.

Regulatory Readiness With a robust quality management system aligned to cGMP, FDA regulations, ISO 17025 and ISO 13485, ZebraSci can address clients’ compliance needs across multiple geographies, reducing regulatory risk and timeline uncertainty for new products.

Global Expansion Potential ZebraSci has multiple geographies of prior commercialization and operates across two large facilities with substantial clean room and lab space, suggesting capacity to scale pilot programs into regional or international launches for clients seeking market expansion.

Financial Leverage Reported revenue in the mid-range of tens of millions and a lean employee base indicate potential for high-value, project-based engagements with favorable margins, especially for clients needing specialized testing without large CRO overhead.

Strategic Alliances Experience supporting incoming inspections, lot release testing, and market complaint investigations, combined with senior leadership hires, points to opportunities for long-term partnerships with larger biotech and pharma firms outsourcing quality, testing, and compliance functions.